Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay

Goldenberger, Daniel; Leuzinger, Karoline; Søgaard, Kirstine Kobberøe; Gosert, Rainer; Roloff, Tim; Naegele, Klaudia; Cuénod, Aline; Mari, Alfredo; Seth-Smith, Helena M. B.; Rentsch, Katharina; Hinić, Vladimira; Hirsch, Hans H.; Egli, Adrian

doi:10.1016/j.jviromet.2020.113925

Cited by 42 publications

(54 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, approval for Emergency Use Authorization (EUA) has been granted by Food and Drug Administration (FDA). Previous studies shown that it has satisfactory performance in detection of SARS-CoV-2 [ [6] , [7] , [8] , [9] ]. In this study, we aimed to evaluate the performance of Xpert Xpress SARS-CoV-2 assay for detection of SARS-CoV-2 from DTS and LRT specimens with sample pre-treatment before testing.…”

Section: Introductionmentioning

confidence: 99%

Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay

Wong

et al. 2020

Journal of Clinical Virology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay

Wong

et al. 2020

Journal of Clinical Virology

View full text Add to dashboard Cite

show abstract

“… 8 , 22 Thus, RT-PCR has become the gold standard technique for COVID-19 diagnosis with newly developed assays providing results in just 45 min. 23 However, a high incidence (between 2 and 29%) of false negative results has raised concerns regarding its diagnostic reliability, particularly in asymptomatic patients. 24 − 27 …”

Section: Diagnosis and Imaging Of Covid-19 Patientsmentioning

confidence: 99%

Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2

Pallares

Abergel

2021

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) outbreak has devastated the healthcare systems and economies of over 200 countries in just a few months. The etiological agent of COVID-19, SARS-CoV-2, is a highly contagious virus that can be transmitted by asymptomatic and symptomatic carriers alike. While in vitro testing techniques have allowed for population-wide screening, prognostic tools are required to assess the disease severity and therapeutic response, contributing to improve the patient clinical outcomes. Moreover, no specific antiviral against COVID-19 exists at the time of publication, severely limiting treatment against the infection. Hence, there is an urgent clinical need for innovative therapeutic strategies that may contribute to manage the COVID-19 outbreak and prevent future pandemics. Herein, we critically examine recent diagnostic, prognostic, and therapeutic advancements for COVID-19 in the field of radiopharmaceuticals. First, we summarize the gold standard techniques used to diagnose COVID-19, including in vitro assays and imaging techniques, and then discuss how radionuclide-based nuclear imaging provides complementary information for prognosis and treatment management of infected patients. Second, we introduce new emerging types of radiotherapies that employ radioimmunoconjugates, which have shown selective cytotoxic response in oncological studies, and critically analyze how these compounds could be used as therapeutic agents against SARS-CoV-2. Finally, this Perspective further discusses the emerging applications of radionuclides to study the behavior of pulmonary SARS-CoV-2 aerosol particles.

show abstract

“…Similar to the detection of other respiratory viruses such as influenza and respiratory syncytial virus, turnaround times for NATs may be reduced by using rapid RT-PCR platforms or loop isothermal amplification (LAMP) methods. 40 Although the RT-PCR assays show comparable performance to the standard non-rapid assays, 41 , 42 the throughput of these assays is generally low, but the reduced turnaround times of less than one hour make these assays useful for certain clinical scenarios where an urgent result is required. LAMP assays are being developed for commercialisation, particularly for point-of-care applications in remote areas or communities with limited laboratory access, given the lack of specialised equipment needed, rapid turnaround times required and with previous data showing comparable performance to RT-PCR.…”

Section: Sars-cov-2 Nucleic Acid Testingmentioning

confidence: 99%

Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2

et al. 2020

View full text Add to dashboard Cite

The first laboratory confirmed case of Coronavirus disease 2019 (COVID-19) in Australia was in Victoria on 25 January 2020 in a man returning from Wuhan city, Hubei province, the People's Republic of China. This was followed by three cases in New South Wales the following day. The Australian Government activated the Australian Health Sector Emergency Response Plan for Novel Coronavirus on 27 February 2020 in anticipation of a pandemic. Subsequently, the World Health Organization declared COVID-19 to be a Public Health Emergency of International Concern followed by a pandemic on 30 January 2020 and 11 March 2020, respectively. Laboratory testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, is key in identifying infected persons to guide timely public health actions of contact tracing and patient isolation to limit transmission of infection. This article aims to provide a comprehensive overview of current laboratory diagnostic methods for SARS-CoV-2, including nucleic acid testing, serology, rapid antigen detection and antibody tests, virus isolation and whole genome sequencing. The relative advantages and disadvantages of the different diagnostic tests are presented, as well as their value in different clinical, infection control and public health contexts. We also describe the challenges in the provision of SARS-CoV-2 diagnostics in Australia, a country with a relatively low COVID-19 incidence in the first pandemic wave but in which prevalence could rapidly change.

show abstract

Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay

Cited by 42 publications

References 6 publications

Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay

Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay

Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2

Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2

Contact Info

Product

Resources

About